WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

WuXi AppTec Reports Strong 2021 Interim Results https://finance.yahoo.com/news/wuxi-apptec-reports-strong-2021-095200729.html • Revenue Up 45.7% Year-Over-Year to RMB10,537 Million • Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million • Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 • Adjusted Non-IFRS[1] Net Profit Attributable to Owners of the Company Up 67.8% Year-Over-Year to RMB2,448 Million • Adjusted Non-IFRS Diluted EPS Up 58.5% Year-Over-Year to RMB0.84 ...

Major Pharmas Broadly Shorted http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/RUM.210812_111612/hk-stock-news ... WUXI APPTEC (02359 HK) and WUXI BIO (02269 HK) likewise slumped for two consecutive days, with the former dropping to as low as $155.5 at one point; last posted $156.2, down 4.5%. The latter, reaching below its 100MA at one point, lasted stood at $118.8, down 3.8%. ...

Vaccine pharmaceutical stocks fell collectively, and WuXi AppTech slumped over 9% https://news.stcn.com/sd/202108/t20210806_3516188.html

WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland https://www.prnewswire.co.uk/news-releases/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland-855233922.html State-of-the-art facility significantly enhances WuXi STA's drug product capacity in Europe while better enabling global customers ...

http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1115772/hk-stock-news JPM: Focus on High-Quality Pharmas Post-correction, Incl. WUXI BIO, WUXI APPTEC

WuXi AppTec (02359 HK) fund shareholders intend to reduce their holdings of 29.52 million A shares https://www.finet.hk/newscenter/news_content/60ff4e5ebde0b337360b8fc8

Pharmasektor allgemein heute betroffen, https://www.finet.hk/newscenter/news_content/60fe18aabde0b337360b8f5e

https://www.contractpharma.com/contents/view_breaking-news/2021-07-22/aptamer-and-wuxi-apptec-form-research-partnership/ Aptamer and WuXi AppTec Form Research Partnership http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1114692/hk-stock-news Some WUXI APPTEC (02359 HK) Directors Plan to Dump 330K Shrs

Zhongtai International: Reiterate WuXi AppTec (02359) "overweight" rating target price raised 18.5% to 203.6 Hong Kong dollars https://hk.investing.com/news/stock-market-news/article-177846

Consun Pharmaceutical (01681) und WuXi AppTec (02359) sind eine strategische Kooperation eingegangen https://wap.eastmoney.com/a/202107192002870128.html

Morgan Stanley: WuXi AppTec (2359 HK) results forecast to beat market expectations and raise target price to HK$200 https://m.jrj.com.cn/madapter/hk/2021/07/16105333106312.shtml According to a research report published by Morgan Stanley, WuXi AppTec (2359 HK)'s initial earnings for the first half of the year beat market expectations. The bank has raised the company's 2021-2024 earnings forecast by 6% to 10%, and its estimates reflect clinical testing services. And the impact of the increase in CDMO/CMO revenue, the expansion of gross profit margin and the decrease in cost-to-expense ratio, the company’s H-share target price was raised from HK$178 to HK$200, and the rating was increased. At the same time, the target under the basic scenario, the bullish and bearish scenario The price rose by 12% to 13%.

WUXI APPTEC Expects 1H NP to Soar Over RMB900M http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02359/NOW.1113078/hk-stock-news WUXI APPTEC (02359 HK) issued a positive profit alert. The net profit attributable to shareholders of the Company was estimated to increase by a range between RMB910 million to RMB944 million for the first half of 2021, as compared with RMB1.717 billion for the first half of 2020, representing a year-over-year increase of a range between 53% to 55%. Im folgenden Artikel noch etwas ausführlicher (Übersetzer nötig): https://www.finet.hk/newscenter/news_content/60f0ee58bde0b337360b8b08

20 ✌️

Die Gründe etwas ausführlicher: CRO stocks plummeted and worries that the new policy reduces the number of orders https://m.hkej.com/landing/mobarticle2/id/2845856/%E3%80%90%E7%95%B0%E5%8B%95%E6%9D%BF%E5%A1%8A%E3%80%91CRO%E8%82%A1%E6%80%A5%E6%8C%AB+%E6%86%82%E6%96%B0%E6%94%BF%E4%BB%A4%E8%A8%82%E5%96%AE%E6%95%B8%E9%87%8F%E9%99%8D

Es fiel noch deutlich tiefer als zum Zeitpunkt des Schreibens 📉: Hong Kong stocks move | WuXi Biologics (02269) fell over 5% and led the decline in CRO concept stock CDE publicly solicits opinions on guiding principles for the development of innovative anti-tumor drugs https://finance.sina.cn/hkstock/ggyw/2021-07-06/detail-ikqcfnca5193370.d.html?from=wap Pharmaceutical outsourcing stocks fell across the board, as of this writing, medicine WuXi biologics (02269) fell 6.38 percent to HK $ 129.2; Tiger medicine (03347) fell 4.12 percent to HK $ 170; into Hong Long (03759) fell 2.75%, report 187.6 Hong Kong dollars; WuXi AppTec (02359) fell 2.4% to 170.8 Hong Kong dollars. On the news, on July 2, the Center for Drug Evaluation (CDE) of the National Medical Products Administration issued the "Notice on the Public Solicitation of Opinions on the Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value". The market tends to believe that the changes in the BSC selected for clinical controlled trials in the draft opinion will affect the prosperity of CXO in the future. Because this change will directly reduce the possibility of drugs developed using the me-too method on the market in the future, which will affect the number of new drug companies' products and reduce the number of orders that CXO companies can obtain.